54464-14-1

Basic information

• Product Name: 5-(4-Methoxyphenyl)-4H-1,2,4-triazol-3-amine
• Synonyms: 5-(4-methoxyphenyl)-1H-1,2,4-triazol-3-amine;5-(4-Methoxyphenyl)-4H-1,2,4-triazol-3-amine;5-(4-Methoxyphenyl)-4H-1,2,4-triazol-3-ylamine;5-(4-methoxyphenyl)-4H-1,2,4-triazol-3-amine(SALTDATA: 0.1H2O);5-(4-methoxyphenyl)-4H-1,2,4-triazol-3-amine 0.1H2O;[5-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl]amine;5-(4-Methoxyphenyl)-2H-1,2,4-triazol-3-amine
• CAS NO: 54464-14-1
• Molecular Formula: C₉H₁₀N₄O
• Molecular Weight: 190.2
• Mol File: 54464-14-1.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 441.8 °C at 760 mmHg
• Flash Point: 221 °C
• Appearance: /
• Density: 1.304 g/cm³
• Vapor Pressure: 5.3E-08mmHg at 25°C
• Refractive Index: 1.637
• CAS DataBase Reference: 5-(4-Methoxyphenyl)-4H-1,2,4-triazol-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-Methoxyphenyl)-4H-1,2,4-triazol-3-amine(54464-14-1)
• EPA Substance Registry System: 5-(4-Methoxyphenyl)-4H-1,2,4-triazol-3-amine(54464-14-1)

Safety Data

• Hazardous Substances Data: 54464-14-1(Hazardous Substances Data)

Usage

General Description

5-(4-Methoxyphenyl)-4H-1,2,4-triazol-3-amine is a chemical compound with the molecular formula C10H10N4O. It is a triazole derivative that has a 1,2,4-triazole core structure with an amine group attached to it. The compound also contains a methoxyphenyl group attached to the triazole ring. It is primarily used in the field of medicinal chemistry and drug discovery, where it may be used as a building block for the synthesis of various pharmaceutical compounds. Its specific roles and applications may vary depending on the specific research or industrial context in which it is used.

InChI:InChI=1/C9H10N4O/c1-14-7-4-2-6(3-5-7)8-11-9(10)13-12-8/h2-5H,1H3,(H3,10,11,12,13)

Upstream product

• 168893-38-7 N-(4-methoxybenzamido)-guanidine 
• 100-07-2 4-methoxy-benzoyl chloride 
• 3290-99-1 4-methoxybenzoic acid hydrazide 
• 100-09-4 4-methoxybenzoic acid 
• 1937-19-5 1-aminoguanidine hydrochloride 
• 168893-38-7 C₉H₁₂N₄O₂ 
• 420-04-2 CYANAMID 
• 19350-72-2 N'-(4-methoxybenzylidene)-4-methylbenzenesulfonohydrazide 
• 123-11-5 4-methoxy-benzaldehyde 
• 121-98-2 methyl 4-methoxybenzoate 
• 23524-07-4 3-chloro-5-(4-methoxy-phenyl)-[1,2,4]oxadiazole 

Downstream Products

• 74258-84-7 3-{1-[(Z)-5-(4-Methoxy-phenyl)-2H-[1,2,4]triazol-3-ylimino]-ethyl}-dihydro-furan-2-one 
• 1456613-86-7 2-(4-methoxyphenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one 
• 924867-16-3 2-(4-methoxyphenyl)-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one 
• 74258-37-0 2-(4-Methoxy-phenyl)-5-methyl-8-(3-pyrrolidin-1-yl-propyl)-7,8-dihydro-6H-pyrrolo[3,2-e][1,2,4]triazolo[1,5-a]pyrimidine 
• 74258-12-1 8-tert-Butyl-2-(4-methoxy-phenyl)-5-methyl-7,8-dihydro-6H-pyrrolo[3,2-e][1,2,4]triazolo[1,5-a]pyrimidine 
• 74258-07-4 8-Isopropyl-2-(4-methoxy-phenyl)-5-methyl-7,8-dihydro-6H-pyrrolo[3,2-e][1,2,4]triazolo[1,5-a]pyrimidine 
• 74258-68-7 7-Chloro-6-(2-chloro-ethyl)-2-(4-methoxy-phenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine 

Relevant articles and documents

Microscale Parallel Synthesis of Acylated Aminotriazoles Enabling the Development of Factor XIIa and Thrombin Inhibitors

Herein we report a microscale parallel synthetic approach allowing for rapid access to libraries of N-acylated aminotriazoles and screening of their inhibitory activity against factor XIIa (FXIIa) and thrombin, which are targets for antithrombotic drugs. This approach, in combination with post-screening structure optimization, yielded a potent 7 nM inhibitor of FXIIa and a 25 nM thrombin inhibitor; both compounds showed no inhibition of the other tested serine proteases. Selected N-acylated aminotriazoles exhibited anticoagulant properties in vitro influencing the intrinsic blood coagulation pathway, but not extrinsic coagulation. Mechanistic studies of FXIIa inhibition suggested that synthesized N-acylated aminotriazoles are covalent inhibitors of FXIIa. These synthesized compounds may serve as a promising starting point for the development of novel antithrombotic drugs.

Diversity-Oriented Synthesis of 1,2,4-Triazols, 1,3,4-Thiadiazols, and 1,3,4-Selenadiazoles from N-Tosylhydrazones

The diversity-oriented synthesis of 1,2,4-triazols, 1,3,4-thiadiazols, and 1,3,4-selenadiazoles from N-tosylhydrazones was developed, and the reactions were general for a wide range of substrates, in which NH2CN, KOCN, KSCN, and KSeCN were used as odorless sources. Two different pathways were proposed, and N-tosylhydrazonoyl chlorides were formed in situ in the presence of NCS.

Synthesis and in vitro anti-epileptic activities of novel [1,2,4]-triazolo[1,5-a]pyrimidin-7(4H)-one derivatives

In this investigation, eight novel 2,5-disubstituted [1,2,4]-triazolo[1,5-a]pyrimidin-7(4H)-one and eight novel 2,5-disubstituted [1,2,4]-triazolo[1,5-a]pyrimidine amine derivatives were synthesized based on the novel marine natural product Essramycin. Their anti-epileptic activities were evaluated by 4-aminopyridine (4-AP)-induced hyper excitability model in primary cultured neocortical neurons. Five compounds with [1,2,4]-triazolo[1,5-a]pyrimidin-7(4H)-one skeleton showed remarkable anti-epileptic activities. The preliminary structure–activity relationship (SAR) showed that the pyrimidine-7(4H)-one motif is the necessary “active core” of anti-epileptic activity. To understand the action mechanism of anti-epileptic activity of [1,2,4]-triazolo[1,5-a]pyrimidin-7(4H)-one compounds, docking studies using the model of GABAA as docking scaffolds were performed and the docking results were in concordance with the experiment observations. (Figure presented.).